TBX 3400
Alternative Names: autologous human peripheral blood mononuclear cells incubated ex vivo with protein TBX-4000 (Tat-MYC); TBX-3400Latest Information Update: 28 Mar 2024
At a glance
- Originator Taiga Biotechnologies
- Class Anti-infectives; Antineoplastics; Antivirals; Cell therapies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cell replacements; Immunologic cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Human papillomavirus infections
- No development reported Hepatitis B; Infections; Malignant melanoma; Solid tumours
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-B in Thailand (IV, Infusion)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Second-line therapy or greater) in Israel (IV, Infusion)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Malignant-melanoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)